Skip to main navigation
X-twitter-square Linkedin Instagram Facebook-square Youtube

NASDAQ: HELP | CBOE CA: HELP

  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials
      • Financials
      • SEC Filings
      • SEDAR Filings
    • Governance
      • Governance Documents
      • Shareholder Materials
      • Our Team
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contact
      • Whistleblower Resources
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us
  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials
      • Financials
      • SEC Filings
      • SEDAR Filings
    • Governance
      • Governance Documents
      • Shareholder Materials
      • Our Team
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contact
      • Whistleblower Resources
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us

News

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
September 22, 2026
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
September 21, 2026
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
September 21, 2026
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
September 10, 2026
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
September 9, 2026
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
September 3, 2026
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
August 18, 2026
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
August 14, 2026
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
August 10, 2026
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
August 3, 2026
  • Current page 1
  • Page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 1 - 10 of 30

Investor Email Alerts

X-twitter-square Linkedin Instagram Facebook-square Youtube

OUR WORK

  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
INVESTORS
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance
  • Whistleblower Resources
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance
  • Whistleblower Resources

ABOUT US

  • Our Team
  • Our Focus
  • Join Us
  • Contact Us
  • Our Team
  • Our Focus
  • Join Us
  • Contact Us

TRADE

  • NASDAQ: HELP
  • CBOE CA: HELP
  • Helus Pharma© 2026. All rights reserved.
  • Privacy Policy
  • Employee Privacy Policy
  • Privacy Notice
Search Investors